Acute Myeloid Leukemia Clinical Trial
Official title:
A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
Verified date | June 2016 |
Source | BioLineRx, Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical research study is to learn if BL-8040 in combination with cytarabine (Ara-C) can help to control the disease in patients with Acute Myeloid Leukemia (AML) that has relapsed or did not respond adequately to previous treatment. The safety of the study drug combination will also be studied.
Status | Completed |
Enrollment | 42 |
Est. completion date | June 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Adult men and women subjects aged 18 to 75, inclusive. 2. Confirmed diagnosis of relapsed/refractory AML (WHO criteria) Refractory subjects, up to second consecutive salvage . Relapsed subjects including first and second relapse. 3. AML relapse > 6 months since autologous or allogeneic stem cell transplantation, provided they are in first or second relapse and: No active graft-versus-host disease (GVHD > grade 1). No treatment with high dose steroids for GVHD (up to 20 mg Prednisolone or equivalent, Appendix G). No treatment with immunosuppressive drugs with the exception of low dose cyclosporine and tacrolimus (blood levels of 0.5-0.6 µg/mL). 4. Clinical laboratory values should be as follows: WBC < 30,000/mL Blasts in PB = 20,000. Treatment with Hydroxyurea is permitted up to 24 hrs prior to BL-8040 administration to achieve blast counts < 20,000 prior to enrollment. Creatinine < 1.3 mg/dL; if Creatinine is > 1 mg/dL the Creatinine clearance should be > 40 mL/min as calculated using the Cockcroft-Gault formula. 5. Women of childbearing potential and all men must agree to use an approved form of contraception (e.g. oral, transdermal patch, implanted contraceptives, intrauterine device, diaphragm, condom, abstinence or surgical sterility) prior to study entry and for the duration of study participation through 30 days after the last dose of BL-8040. Confirmation that female subjects are not pregnant must be established by a negative serum ß-human chorionic gonadotropin (ß-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. 6. Subject is able and willing to comply with the requirements of the protocol. 7. Subject is able to voluntarily provide written informed consent. Exclusion Criteria: 1. Administration of conventional chemotherapy within 2 weeks of enrollment date. In the event that subjects have received chemotherapy > 2 weeks from the date of enrollment, they may be included provided they have recovered from the associated non-hematological toxicities to = grade 1. 2. Life expectancy of = 2 months. 3. Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product. 4. Use of investigational device or agents within 2 weeks of enrollment date. 5. Low Performance Status (ECOG > 2; Appendix E). 6. O2 saturation < 92% (on room air), evidence of TLS > grade 2 (according to the Cairo-Bishop criteria (3)) or leukostasis (2). 7. Abnormal liver function tests: Serum aspartate transaminase (AST/SGOT) or alanine transaminase ( ALT/SGPT) 2 x upper limit of normal (ULN). Serum bilirubin. Total bilirubin > 2.0 mg/dL (34 µmol/L), conjugated bilirubin > 0.8 mg/dL. 8. Left ventricular ejection fraction < 40 %. 9. History of myocardial infarction or cerebrovascular accident within 6 months of enrollment date. 10. Presence of active, uncontrolled infection. 11. Known central nervous system disease (e.g., Alzheimer's disease). 12. Acute promyelocytic leukemia. 13. Exposure to high dose Ara-C within 6 months of enrollment. 14. Subject has concurrent, uncontrolled medical condition, laboratory abnormality, or psychiatric illness which could place him/her at unacceptable risk, including, but not limited to: Subject has been diagnosed or treated for another malignancy within 3 years of enrolment, except in situ malignancy, or low-risk prostate, skin or cervix cancer after curative therapy A co-morbid condition which, in the view of the Investigators, renders the subject at high risk from treatment complications. 15. Female subjects who are pregnant or breastfeeding. 16. Prior clinically significant grade 3-4 non-hematological toxicity to high dose Ara-C or grade = 2 of neurological toxicity. 17. Seropositive for HIV antibodies (HIV1 and HIV2), Hepatitis C antibody (Hep C Ab) or a Hepatitis B carrier (positive for Hepatitis B surface antigen [HBsAg]). 18. Unable to comply with study requirements in the opinion of the Investigator. |
Country | Name | City | State |
---|---|---|---|
Israel | Rambam Medical Center | Haifa | |
Israel | Shaare Zedek Medical Center | Jerusalem | |
Israel | Meir Medical Center | Kfar Saba | |
Israel | Chaim Sheba Medical Center | Ramat Gan | |
Israel | Tel-Aviv Sourasky Medical Center | Tel Aviv | |
United States | Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Mayo Clinic | Jacksonville | Florida |
United States | Memorial Sloan-Kettering Cancer Center | New York | New York |
United States | Washington University School of Medicine | St. Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
BioLineRx, Ltd. |
United States, Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Pharmacodynamic parameters | To assess additional pharmacodynamic parameters relevant to CXCR4 inhibition by CXCR4 receptor occupancy | After end of study- an expected average of 6 weeks. | |
Primary | Safety and tolerability | General safety: Vital signs (oral temperature, blood pressure, pulse rate, respiratory rate and O2 saturation), 12-lead ECG and physical examination. Toxicity according to the latest version of NCI-CTCAE (currently V4.03, refer to ) for AEs and clinical laboratory profile as follows: Screening: record and report screening results, however not considered treatment emergent AEs. Throughout the study: record and report all AEs and SAEs according to GCP. |
"participants will be followed for the duration of hospital stay and the follow up period, an expected average of 6 weeks. | |
Secondary | Clinical efficacy | The outcome will be measured by response rates as assessed at final Bone Marrow evaluation based on Cheson 2003 criteria. | Final Bone Marrow evaluation -Between day 20 and day 44 | |
Secondary | Apoptotic effect | Change in leukemic cell apoptosis in Peripheral Blood and Bone Marrow. | Final evaluation- between day 20 and day 44 | |
Secondary | Mobilization | Mobilization of AML blasts from the bone marrow to the peripheral blood (PB) by cell counting | Final evaluation- between day 20 and day 44 | |
Secondary | Pharmacokinetic profile | Cmax - maximum BL-8040 plasma concentration Tmax - time to reach the maximum BL-8040 plasma concentration AUC0-t - Area under the BL-8040 plasma concentration-time curve AUC0-8 - Area under the BL-8040 plasma concentration-time curve ?z - elimination rate constant, determined by linear regression t1/2 - terminal elimination half-life, defined as 0.693/?z |
Day 0 to day 7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |